{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:00:59Z","timestamp":1749528059563,"version":"3.41.0"},"publisher-location":"Cham","reference-count":260,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031849879","type":"print"},{"value":"9783031849886","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-84988-6_2","type":"book-chapter","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:11Z","timestamp":1749452171000},"page":"9-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic Transplantation for Older Adults"],"prefix":"10.1007","author":[{"given":"Ashley D.","family":"Hadjis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon R.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"10","key":"2_CR1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bbmt.2016.06.010","volume":"22","author":"R Abboud","year":"2016","unstructured":"Abboud R, Keller J, Slade M et al (2016) Severe cytokine-release syndrome after T cell\u2013replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti\u2013IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant 22(10):1851\u20131860","journal-title":"Biol Blood Marrow Transplant"},{"key":"2_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2021-144591","volume":"138","author":"R Abboud","year":"2021","unstructured":"Abboud R, Gao F, Rettig MP et al (2021) A single-arm, open-label, pilot study of the JAK1 selective inhibitor itacitinib for the prophylaxis of graft-versus-host disease and cytokine release syndrome in T-cell replete haploidentical peripheral blood hematopoietic cell transplantation. Blood 138:100. https:\/\/doi.org\/10.1182\/blood-2021-144591","journal-title":"Blood"},{"issue":"9","key":"2_CR3","doi-asserted-by":"publisher","first-page":"578.e1","DOI":"10.1016\/j.jtct.2023.06.020","volume":"29","author":"MB Abid","year":"2023","unstructured":"Abid MB, Estrada-Merly N, Zhang M-J et al (2023) Impact of donor age on allogeneic hematopoietic cell transplantation outcomes in older adults with acute myeloid leukemia. Transplant Cell Ther 29(9):578.e1\u2013578.e9. https:\/\/doi.org\/10.1016\/j.jtct.2023.06.020","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2_CR4","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2215\/cjn.19801220","volume":"16","author":"MH Abramson","year":"2021","unstructured":"Abramson MH, Gutgarts V, Zheng J et al (2021) Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation. Clin J Am Soc Nephrol 16(9):1318\u20131327. https:\/\/doi.org\/10.2215\/cjn.19801220","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Supplement 1","key":"2_CR5","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1182\/blood-2021-153455","volume":"138","author":"H Ackula","year":"2021","unstructured":"Ackula H, Medawar G, Cerio C, Roberts TF, Meleveedu K (2021) De-escalation of Ptcy dosing in matched allogenic transplants: a single institution retrospective study. Blood 138(Supplement 1):4872\u20134872. https:\/\/doi.org\/10.1182\/blood-2021-153455","journal-title":"Blood"},{"issue":"9","key":"2_CR6","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1182\/bloodadvances.2020001499","volume":"4","author":"MM Al Malki","year":"2020","unstructured":"Al Malki MM, Yang D, Labopin M et al (2020) Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv 4(9):2073\u20132083. https:\/\/doi.org\/10.1182\/bloodadvances.2020001499","journal-title":"Blood Adv"},{"issue":"1","key":"2_CR7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","volume":"53","author":"HK Al-Ali","year":"2012","unstructured":"Al-Ali HK, Jaekel N, Junghanss C et al (2012) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study. Leuk Lymphoma 53(1):110\u2013117","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ejh.13482","volume":"106","author":"R Alblooshi","year":"2021","unstructured":"Alblooshi R, Kanfar S, Lord B et al (2021) Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol 106(1):32\u201339. https:\/\/doi.org\/10.1111\/ejh.13482","journal-title":"Eur J Haematol"},{"issue":"14","key":"2_CR9","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/bloodadvances.2023010545","volume":"7","author":"AS Al-Homsi","year":"2023","unstructured":"Al-Homsi AS, Cirrone F, Wo S et al (2023) PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv 7(14):3604\u20133611. https:\/\/doi.org\/10.1182\/bloodadvances.2023010545","journal-title":"Blood Adv"},{"issue":"5","key":"2_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","volume":"6","author":"H Ali","year":"2022","unstructured":"Ali H, Tsai NC, Synold T et al (2022) Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 6(5):1444\u20131453. https:\/\/doi.org\/10.1182\/bloodadvances.2021005035","journal-title":"Blood Adv."},{"issue":"13","key":"2_CR11","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/blood-2012-08-453860","volume":"121","author":"AM Alousi","year":"2013","unstructured":"Alousi AM, Le-Rademacher J, Saliba RM et al (2013) Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood 121(13):2567\u20132573. https:\/\/doi.org\/10.1182\/blood-2012-08-453860","journal-title":"Blood"},{"issue":"11","key":"2_CR12","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1054\/bjoc.2001.2162","volume":"85","author":"M Ando","year":"2001","unstructured":"Ando M, Ando Y, Hasegawa Y et al (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85(11):1634\u20131639. https:\/\/doi.org\/10.1054\/bjoc.2001.2162","journal-title":"Br J Cancer"},{"key":"2_CR13","doi-asserted-by":"publisher","unstructured":"Andronesi A, Sorohan B, Burcea A et al (2022) Incidence and risk factors for acute kidney injury after allogeneic stem cell transplantation: a prospective study. Biomedicines 10(2). https:\/\/doi.org\/10.3390\/biomedicines10020262","DOI":"10.3390\/biomedicines10020262"},{"issue":"4","key":"2_CR14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbmt.2017.01.006","volume":"23","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Horak D, Scott JM et al (2017) Cardiovascular function in long-term hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 23(4):700\u2013705. https:\/\/doi.org\/10.1016\/j.bbmt.2017.01.006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1182\/asheducation-2016.1.99","volume":"2016","author":"AS Artz","year":"2016","unstructured":"Artz AS (2016) Biologic vs physiologic age in the transplant candidate. Hematology Am Soc Hematol Educ Program 2016(1):99\u2013105. https:\/\/doi.org\/10.1182\/asheducation-2016.1.99","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Supplement 1","key":"2_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/blood-2023-173855","volume":"142","author":"A Artz","year":"2023","unstructured":"Artz A, Logan BR, Saber W et al (2023) The Composite Health Risk Assessment Model (CHARM) to predict 1-year Non-Relapse Mortality (NRM) among older recipients of allogeneic transplantation: a prospective BMT-CTN Study 1704. Blood 142(Supplement 1):109\u2013109. https:\/\/doi.org\/10.1182\/blood-2023-173855","journal-title":"Blood"},{"issue":"6","key":"2_CR17","doi-asserted-by":"publisher","first-page":"346.e1","DOI":"10.1016\/j.jtct.2023.03.007","volume":"29","author":"JJ Auletta","year":"2023","unstructured":"Auletta JJ, Kou J, Chen M et al (2023) Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the center for international blood and marrow transplant research. Transplant Cell Ther 29(6):346.e1\u2013346.e10. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.007","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41409-022-01833-0","volume":"58","author":"D Backhaus","year":"2023","unstructured":"Backhaus D, Brauer D, Pointner R et al (2023) A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. Bone Marrow Transplant 58(1):30\u201338. https:\/\/doi.org\/10.1038\/s41409-022-01833-0","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2_CR19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","volume":"121","author":"F Baron","year":"2015","unstructured":"Baron F, Labopin M, Peniket A et al (2015) Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the A cute L eukemia W orking P arty of the E uropean G roup for B lood and M arrow T ransplantation. Cancer 121(7):1048\u20131055","journal-title":"Cancer"},{"key":"2_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1182\/blood-2023-179489","volume":"142","author":"A Bazarbachi","year":"2023","unstructured":"Bazarbachi A, Labopin M, Moukalled N et al (2023) How much have post-transplant outcomes improved since 2000 for older patients with acute myeloid leukemia? A study from the EBMT acute leukemia working party. Blood 142:896. https:\/\/doi.org\/10.1182\/blood-2023-179489","journal-title":"Blood"},{"issue":"25","key":"2_CR21","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar R, Stevenson KE, Caughey B et al (2014) Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol 32(25):2691","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jtct.2021.10.002","volume":"28","author":"VR Bhatt","year":"2022","unstructured":"Bhatt VR, Wang T, Chen K et al (2022) Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell transplantation: a center for international blood and marrow transplant research analysis. Transplant Cell Ther. 28(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jtct.2021.10.002","journal-title":"Transplant Cell Ther."},{"issue":"9","key":"2_CR23","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/cncr.21418","volume":"104","author":"DP Blaise","year":"2005","unstructured":"Blaise DP, Michel Boiron J, Faucher C et al (2005) Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104(9):1931\u20131938. https:\/\/doi.org\/10.1002\/cncr.21418","journal-title":"Cancer"},{"issue":"7","key":"2_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.31885","volume":"125","author":"PC Boddu","year":"2019","unstructured":"Boddu PC, Kadia TM, Garcia-Manero G et al (2019) Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes. Cancer 125(7):1091\u20131100. https:\/\/doi.org\/10.1002\/cncr.31885","journal-title":"Cancer"},{"key":"2_CR25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-12-397898-1.00005-0","volume":"125","author":"C Bodelon","year":"2014","unstructured":"Bodelon C, Savage SA, Gadalla SM (2014) Telomeres in molecular epidemiology studies. Prog Mol Biol Transl Sci 125:113\u2013131","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2_CR26","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2021-146163","volume":"138","author":"N Boissel","year":"2021","unstructured":"Boissel N, Huguet F, Graux C et al (2021) Frontline consolidation with blinatumomab for high-risk philadelphia-negative acute lymphoblastic adult patients. Early results from the Graall-2014-QUEST Phase 2. Blood 138:1232","journal-title":"Blood"},{"issue":"25","key":"2_CR27","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J et al (2023) Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 388(25):2338\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa2215943","journal-title":"N Engl J Med."},{"key":"2_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Moiseev I et al (2020) Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J Hematol Oncol 13:1\u201310","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2_CR29","doi-asserted-by":"crossref","first-page":"125.e1","DOI":"10.1016\/j.jtct.2022.11.020","volume":"29","author":"L Broglie","year":"2023","unstructured":"Broglie L, Friend BD, Chhabra S et al (2023) Expanded HCT-CI definitions capture comorbidity better for younger patients of allogeneic HCT for nonmalignant diseases. Transplant Cell Ther 29(2):125.e1\u2013125.e9","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjh.14033","volume":"174","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Wells RA, Zhu N et al (2016) Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol 174(1):88\u2013101. https:\/\/doi.org\/10.1111\/bjh.14033","journal-title":"Br J Haematol"},{"issue":"1","key":"2_CR31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/07853890.2022.2164610","volume":"55","author":"XY Cao","year":"2023","unstructured":"Cao XY, Chen JQ, Wang H et al (2023) Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML. Ann Med 55(1):388\u2013400. https:\/\/doi.org\/10.1080\/07853890.2022.2164610","journal-title":"Ann Med"},{"issue":"4","key":"2_CR32","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28(4):556\u2013561","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","volume":"20","author":"S Church","year":"2020","unstructured":"Church S, Rogers E, Rockwood K, Theou O (2020) A scoping review of the clinical frailty scale. BMC Geriatr 20(1):393. https:\/\/doi.org\/10.1186\/s12877-020-01801-7","journal-title":"BMC Geriatr"},{"issue":"8","key":"2_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA et al (2015) Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 126(8):1033\u20131040. https:\/\/doi.org\/10.1182\/blood-2015-04-639831","journal-title":"Blood."},{"issue":"6","key":"2_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood.2019003662","volume":"135","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Kongtim P, Varma A et al (2020) Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood 135(6):449\u2013452. https:\/\/doi.org\/10.1182\/blood.2019003662","journal-title":"Blood"},{"issue":"2","key":"2_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A et al (2019) Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33(2):379\u2013389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9","journal-title":"Leukemia"},{"issue":"6","key":"2_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056147","volume":"12","author":"AB Coulson","year":"2022","unstructured":"Coulson AB, Royle K-L, Pawlyn C et al (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open 12(6):e056147. https:\/\/doi.org\/10.1136\/bmjopen-2021-056147","journal-title":"BMJ Open"},{"issue":"11\u201312","key":"2_CR38","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1159\/000533945","volume":"52","author":"K Cui","year":"2023","unstructured":"Cui K, Zhang S, Li J (2023) Risk factors for acute kidney injury after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Blood Purif 52(11\u201312):917\u2013928. https:\/\/doi.org\/10.1159\/000533945","journal-title":"Blood Purif"},{"key":"2_CR39","doi-asserted-by":"publisher","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","volume":"30","author":"R Cusatis","year":"2024","unstructured":"Cusatis R, Litovich C, Feng Z et al (2024) Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the center for international blood and marrow transplant research registry. Transplant Cell Ther. 30:917.e1. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.021","journal-title":"Transplant Cell Ther."},{"issue":"22","key":"2_CR40","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"138","author":"C Cutler","year":"2021","unstructured":"Cutler C, Lee SJ, Arai S et al (2021) Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood 138(22):2278\u20132289. https:\/\/doi.org\/10.1182\/blood.2021012021","journal-title":"Blood"},{"issue":"1","key":"2_CR41","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/CIRCGENETICS.113.000485","volume":"8","author":"MJJ D\u2019Mello","year":"2015","unstructured":"D\u2019Mello MJJ, Ross SA, Briel M, Anand SS, Gerstein H, Par\u00e9 G (2015) Association between shortened leukocyte telomere length and cardiometabolic outcomes. Circ Cardiovasc Genetics 8(1):82\u201390. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000485","journal-title":"Circ Cardiovasc Genetics"},{"key":"2_CR42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/OP.22.00197","volume":"18","author":"W Dale","year":"2022","unstructured":"Dale W (2022) Why is geriatric assessment so infrequently used in oncology practices? The ongoing issue of nonadherence to this standard of care for older adults with cancer. JCO Oncol Pract (Wolters Kluwer Health) 18:475\u2013477","journal-title":"JCO Oncol Pract (Wolters Kluwer Health)"},{"issue":"6","key":"2_CR43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/OP.20.00442","volume":"17","author":"W Dale","year":"2021","unstructured":"Dale W, Williams GR, MacKenzie AR et al (2021) How is geriatric assessment used in clinical practice for older adults with cancer? A survey of cancer providers by the American Society of Clinical Oncology. JCO Oncol Pract 17(6):336\u2013344","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"2_CR44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bbmt.2016.04.026","volume":"22","author":"M Damlaj","year":"2016","unstructured":"Damlaj M, Alkhateeb HB, Hefazi M et al (2016) Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing. Biol Blood Marrow Transplant 22(8):1431\u20131439","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2_CR45","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2017-06-746412","volume":"131","author":"G de Haan","year":"2018","unstructured":"de Haan G, Lazare SS (2018) Aging of hematopoietic stem cells. Blood. 131(5):479\u2013487","journal-title":"Blood."},{"issue":"3","key":"2_CR46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","volume":"104","author":"M de Lima","year":"2004","unstructured":"de Lima M, Anagnostopoulos A, Munsell M et al (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 104(3):865\u2013872. https:\/\/doi.org\/10.1182\/blood-2003-11-3750","journal-title":"Blood."},{"issue":"3","key":"2_CR47","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","volume":"29","author":"D DeAngelo","year":"2015","unstructured":"DeAngelo D, Stevenson K, Dahlberg S et al (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29(3):526\u2013534","journal-title":"Leukemia"},{"issue":"2","key":"2_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","volume":"29","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Ciurea SO, Cutler C et al (2023a) Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther 29(2):71\u201381. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.014","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"2_CR49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1182\/blood-2023-180423","volume":"142","author":"Z Defilipp","year":"2023","unstructured":"Defilipp Z, Kim HT, Knight L et al (2023b) Maintenance ruxolitinib is associated with low rates of chronic Gvhd requiring systemic treatment in older adults with AML\/MDS undergoing allogeneic HCT: results of a phase II multicenter trial. Blood 142(Supplement 1):653\u2013653. https:\/\/doi.org\/10.1182\/blood-2023-180423","journal-title":"Blood"},{"issue":"35","key":"2_CR50","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"SM Devine","year":"2015","unstructured":"Devine SM, Owzar K, Blum W et al (2015) Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)\/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol 33(35):4167","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR51","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1182\/asheducation-2016.1.543","volume":"2016","author":"R Devlin","year":"2016","unstructured":"Devlin R, Gupta V (2016) Myelofibrosis: to transplant or not to transplant? Hematology Am Soc Hematol Educ Program 2016(1):543\u2013551. https:\/\/doi.org\/10.1182\/asheducation-2016.1.543","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2_CR52","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1182\/bloodadvances.2019000394","volume":"4","author":"AE DeZern","year":"2020","unstructured":"DeZern AE, Gondek LP (2020) Stem cell donors should be screened for CHIP. Blood Adv. 4(4):784\u2013788. https:\/\/doi.org\/10.1182\/bloodadvances.2019000394","journal-title":"Blood Adv."},{"key":"2_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-4-39","volume":"4","author":"HR Diamond","year":"2011","unstructured":"Diamond HR, Ornellas MH, Orfao A et al (2011) Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. J Hematol Oncol 4:1\u20138","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2_CR54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A et al (2018) Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(2):216\u2013228","journal-title":"Lancet Oncol"},{"issue":"7","key":"2_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"issue":"3","key":"2_CR56","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/STROKEAHA.111.637207","volume":"43","author":"H Ding","year":"2012","unstructured":"Ding H, Chen C, Shaffer JR et al (2012) Telomere length and risk of stroke in Chinese. Stroke 43(3):658\u2013663","journal-title":"Stroke"},{"key":"2_CR57","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.33549\/physiolres.932856","volume":"63","author":"D Dlouha","year":"2014","unstructured":"Dlouha D, Maluskova J, Lesna IK, Lanska V, Hubacek J (2014) Comparison of the relative telomere length measured in leukocytes and eleven different human tissues. Physiol Res 63:S343","journal-title":"Physiol Res"},{"issue":"4","key":"2_CR58","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"3","key":"2_CR59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts. Blood 126(3):291\u2013299","journal-title":"Blood"},{"issue":"9","key":"2_CR60","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","volume":"60","author":"H Dombret","year":"2019","unstructured":"Dombret H, Topp MS, Schuh AC et al (2019) Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 60(9):2214\u20132222","journal-title":"Leuk Lymphoma"},{"key":"2_CR61","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2021-149165","volume":"138","author":"S Dwabe","year":"2021","unstructured":"Dwabe S, Martinez H, Rodman J et al (2021) Evaluating outcomes using post-transplant cyclophosphamide\/tacrolimus\/mycophenolate mofetil as gvhd prophylaxis compared with methotrexate\/tacrolimus in matched-related and matched-unrelated hematopoietic stem cell transplant in relation to the haploidentical setting in acute lymphoblastic leukemia: a single center experience. Blood 138:4874. https:\/\/doi.org\/10.1182\/blood-2021-149165","journal-title":"Blood"},{"key":"2_CR62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2016.11.002","volume":"54","author":"HK Elias","year":"2017","unstructured":"Elias HK, Bryder D, Park CY (2017) Molecular mechanisms underlying lineage bias in aging hematopoiesis. Semin Hematol (Elsevier) 54:4\u201311","journal-title":"Semin Hematol (Elsevier)"},{"issue":"12","key":"2_CR63","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.bbmt.2020.09.013","volume":"26","author":"C Flannelly","year":"2020","unstructured":"Flannelly C, Tan BEX, Tan JL et al (2020) Barriers to hematopoietic cell transplantation for adults in the United States: a systematic review with a focus on age. Biol Blood Marrow Transplant 26(12):2335\u20132345. https:\/\/doi.org\/10.1016\/j.bbmt.2020.09.013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2_CR64","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA et al (2011) Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 117(11):3214\u20133219","journal-title":"Blood"},{"issue":"5","key":"2_CR65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.19.01892","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Shaw PA, Hexner EO et al (2020) Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 38(5):415\u2013422. https:\/\/doi.org\/10.1200\/JCO.19.01892","journal-title":"J Clin Oncol."},{"issue":"9","key":"2_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jtct.2022.06.018","volume":"28","author":"CW Freyer","year":"2022","unstructured":"Freyer CW, Babushok DV, Frey NV et al (2022) Low-dose total body irradiation added to fludarabine and busulfan reduced-intensity conditioning reduces graft failure in patients with myelofibrosis. Transplant Cell Ther 28(9):590\u2013596. https:\/\/doi.org\/10.1016\/j.jtct.2022.06.018","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2_CR67","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","volume":"37","author":"M Frick","year":"2019","unstructured":"Frick M, Chan W, Arends CM et al (2019) Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 37(5):375\u2013385","journal-title":"J Clin Oncol"},{"issue":"3","key":"2_CR68","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.m146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56(3):M146\u2013M156. https:\/\/doi.org\/10.1093\/gerona\/56.3.m146","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"10","key":"2_CR69","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood.2021013443","volume":"139","author":"EJ Fuchs","year":"2022","unstructured":"Fuchs EJ, McCurdy SR, Solomon SR et al (2022) HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood 139(10):1452\u20131468. https:\/\/doi.org\/10.1182\/blood.2021013443","journal-title":"Blood"},{"issue":"7","key":"2_CR70","doi-asserted-by":"crossref","first-page":"e1081","DOI":"10.1200\/OP.21.00743","volume":"18","author":"A Gajra","year":"2022","unstructured":"Gajra A, Jeune-Smith Y, Fortier S et al (2022) The use and knowledge of validated geriatric assessment instruments among US community oncologists. JCO Oncol Pract 18(7):e1081\u2013e1090","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"2_CR71","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1365-2141.1987.tb06160.x","volume":"67","author":"RP Gale","year":"1987","unstructured":"Gale RP, Bortin MM, van Bekkum DW et al (1987) Risk factors for acute graft-versus-host disease. Br J Haematol 67(4):397\u2013406. https:\/\/doi.org\/10.1111\/j.1365-2141.1987.tb06160.x","journal-title":"Br J Haematol"},{"issue":"1","key":"2_CR72","doi-asserted-by":"publisher","first-page":"49.e1","DOI":"10.1016\/j.jtct.2022.10.015","volume":"29","author":"M Gambella","year":"2023","unstructured":"Gambella M, Bregante S, Raiola AM et al (2023) Haploidentical hematopoietic cell transplantation for myelofibrosis in the ruxolitinib era. Transplant Cell Therapy 29(1):49.e1\u201349.e7. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.015","journal-title":"Transplant Cell Therapy"},{"issue":"11","key":"2_CR73","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, Johnson IM et al (2023) Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 108(11):3170\u20133174. https:\/\/doi.org\/10.3324\/haematol.2022.282677","journal-title":"Haematologica"},{"issue":"24","key":"2_CR74","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","volume":"5","author":"JS Garcia","year":"2021","unstructured":"Garcia JS, Kim HT, Murdock HM et al (2021) Adding venetoclax to fludarabine\/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv 5(24):5536\u20135545. https:\/\/doi.org\/10.1182\/bloodadvances.2021005566","journal-title":"Blood Adv"},{"issue":"7","key":"2_CR75","doi-asserted-by":"publisher","first-page":"473.e1","DOI":"10.1016\/j.jtct.2023.04.008","volume":"29","author":"I Garc\u00eda-Cadenas","year":"2023","unstructured":"Garc\u00eda-Cadenas I, Redondo S, Esquirol A et al (2023) Successful outcome in patients with myelofibrosis undergoing allogeneic donor hematopoietic cell transplantation using reduced doses of post-transplantation cyclophosphamide: challenges and review of the literature. Transplant Cell Ther 29(7):473.e1\u2013473.e6. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.008","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2_CR76","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371(26):2477\u20132487","journal-title":"N Engl J Med"},{"issue":"20","key":"2_CR77","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood.2022016194","volume":"140","author":"A Ghobadi","year":"2022","unstructured":"Ghobadi A, Slade M, Kantarjian H et al (2022) The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood 140(20):2101\u20132112. https:\/\/doi.org\/10.1182\/blood.2022016194","journal-title":"Blood"},{"issue":"1","key":"2_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2017-01-764951","volume":"130","author":"CJ Gibson","year":"2017","unstructured":"Gibson CJ, Kennedy JA, Nikiforow S et al (2017) Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood 130(1):91\u201394. https:\/\/doi.org\/10.1182\/blood-2017-01-764951","journal-title":"Blood"},{"issue":"2","key":"2_CR79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson CJ, Kim HT, Zhao L et al (2022) Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol 40(2):189\u2013201. https:\/\/doi.org\/10.1200\/JCO.21.02286","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"2_CR81","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2022-158934","volume":"140","author":"N Goekbuget","year":"2022","unstructured":"Goekbuget N, Viardot A, Steffen B et al (2022) Outcome of 841 older patients (> 55 yrs) with newly diagnosed Ph\/BCR-ABL negative ALL prospectively treated according to pediatric-based, age-adapted GMALL protocols. Blood 140(Supplement 1):121\u2013123","journal-title":"Blood"},{"issue":"9","key":"2_CR82","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","volume":"120","author":"N G\u00f6kbuget","year":"2012","unstructured":"G\u00f6kbuget N, Kneba M, Raff T et al (2012) Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120(9):1868\u20131876. https:\/\/doi.org\/10.1182\/blood-2011-09-377713","journal-title":"Blood"},{"issue":"14","key":"2_CR83","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"issue":"11","key":"2_CR84","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H et al (2020) Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 61(11):2665\u20132673","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2_CR85","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood. 111(4):1827\u20131833. https:\/\/doi.org\/10.1182\/blood-2007-10-116582","journal-title":"Blood."},{"issue":"9","key":"2_CR86","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/leu.2016.63","volume":"30","author":"LP Gondek","year":"2016","unstructured":"Gondek LP, Zheng G, Ghiaur G et al (2016) Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 30(9):1916\u20131920","journal-title":"Leukemia"},{"issue":"9","key":"2_CR87","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","volume":"4","author":"K Gowin","year":"2020","unstructured":"Gowin K, Ballen K, Ahn KW et al (2020) Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 4(9):1965\u20131973. https:\/\/doi.org\/10.1182\/bloodadvances.2019001084","journal-title":"Blood Adv"},{"issue":"11","key":"2_CR88","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1182\/blood-2010-04-278317","volume":"116","author":"V Gupta","year":"2010","unstructured":"Gupta V, Tallman MS, He W et al (2010) Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 116(11):1839\u20131848","journal-title":"Blood"},{"issue":"7","key":"2_CR89","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41409-020-0843-3","volume":"55","author":"G Guti\u00e9rrez-Garc\u00eda","year":"2020","unstructured":"Guti\u00e9rrez-Garc\u00eda G, Villarreal J, Garrote M et al (2020) Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. Bone Marrow Transplant 55(7):1264\u20131271","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2_CR90","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1200\/jco.2009.27.1460","volume":"28","author":"B Gyurkocza","year":"2010","unstructured":"Gyurkocza B, Storb R, Storer BE et al (2010) Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 28(17):2859\u20132867. https:\/\/doi.org\/10.1200\/jco.2009.27.1460","journal-title":"J Clin Oncol."},{"key":"2_CR91","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2023-188978","volume":"142","author":"AD Hadjis","year":"2023","unstructured":"Hadjis AD, White GW, Catania C et al (2023) Frail and pre-frail older adults with acute myeloid leukemia have inferior survival due to higher rates of disease-related deaths. Blood 142:376. https:\/\/doi.org\/10.1182\/blood-2023-188978","journal-title":"Blood"},{"issue":"2","key":"2_CR92","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.1016\/j.jtct.2023.12.575","volume":"30","author":"AD Hadjis","year":"2024","unstructured":"Hadjis AD, White GW, Gill SI et al (2024) Post-transplant frailty phenotype predicts survival. Transplant Cell Ther 30(2):S407\u2013S408. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.575","journal-title":"Transplant Cell Ther"},{"issue":"35","key":"2_CR93","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2008.17.6545","volume":"26","author":"T Hahn","year":"2008","unstructured":"Hahn T, McCarthy PL Jr, Zhang M-J et al (2008) Risk factors for acute graft-versus-host disease after human leukocyte antigen\u2013identical sibling transplants for adults with leukemia. J Clin Oncol 26(35):5728\u20135734","journal-title":"J Clin Oncol"},{"issue":"6","key":"2_CR94","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jgo.2022.04.008","volume":"13","author":"M Hamaker","year":"2022","unstructured":"Hamaker M, Lund C, Te Molder M et al (2022) Geriatric assessment in the management of older patients with cancer\u2013a systematic review (update). J Geriatr Oncol 13(6):761\u2013777","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"2_CR95","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2017.04.003","volume":"23","author":"BK Hamilton","year":"2017","unstructured":"Hamilton BK, Rybicki L, Abounader D et al (2017) Allogeneic hematopoietic cell transplantation for adult T cell acute lymphoblastic leukemia. Biol Blood Marrow Transplant 23(7):1117\u20131121. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2_CR96","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 133(15):1652\u20131663. https:\/\/doi.org\/10.1182\/blood-2018-11-883710","journal-title":"Blood."},{"issue":"10","key":"2_CR97","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/ajh.26279","volume":"96","author":"JC Hern\u00e1ndez-Boluda","year":"2021","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Kr\u00f6ger N et al (2021) Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. Am J Hematol 96(10):1186\u20131194. https:\/\/doi.org\/10.1002\/ajh.26279","journal-title":"Am J Hematol"},{"issue":"7","key":"2_CR98","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2017.104","volume":"31","author":"S Herold","year":"2017","unstructured":"Herold S, Kuhn M, Stange T et al (2017) Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia 31(7):1637\u20131640","journal-title":"Leukemia"},{"issue":"8","key":"2_CR99","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/leu.2016.31","volume":"30","author":"P Hirsch","year":"2016","unstructured":"Hirsch P, Mamez A, Belhocine R et al (2016) Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. Leukemia 30(8):1756\u20131759","journal-title":"Leukemia"},{"issue":"8","key":"2_CR100","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41409-023-01966-w","volume":"58","author":"K Hirschb\u00fchl","year":"2023","unstructured":"Hirschb\u00fchl K, Labopin M, Polge E et al (2023) Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years\u2014a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 58(8):874\u2013880. https:\/\/doi.org\/10.1038\/s41409-023-01966-w","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2_CR101","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/jco.23.01392","volume":"42","author":"A Hodder","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A et al (2024) Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol. 42(8):907\u2013914. https:\/\/doi.org\/10.1200\/jco.23.01392","journal-title":"J Clin Oncol."},{"issue":"4","key":"2_CR102","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","volume":"5","author":"HM Holmes","year":"2014","unstructured":"Holmes HM, Des Bordes JK, Kebriaei P et al (2014) Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol 5(4):422\u2013430. https:\/\/doi.org\/10.1016\/j.jgo.2014.04.004","journal-title":"J Geriatr Oncol"},{"issue":"Supplement 1","key":"2_CR103","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1182\/blood-2023-187859","volume":"142","author":"SG Holtan","year":"2023","unstructured":"Holtan SG, Martens MJ, Al Malki MM et al (2023) Patient-reported outcomes of BMT CTN 1703: a randomized phase III study for Gvhd Prophylaxis \u2013 a quality of life evaluation. Blood 142(Supplement 1):897\u2013897. https:\/\/doi.org\/10.1182\/blood-2023-187859","journal-title":"Blood"},{"issue":"12","key":"2_CR104","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/jco.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G et al (2020) Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 38(12):1273\u20131283. https:\/\/doi.org\/10.1200\/jco.19.03011","journal-title":"J Clin Oncol."},{"issue":"1","key":"2_CR105","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbmt.2019.08.022","volume":"26","author":"LW Huang","year":"2020","unstructured":"Huang LW, Sheng Y, Andreadis C et al (2020) Functional status as measured by geriatric assessment predicts inferior survival in older allogeneic hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant 26(1):189\u2013196. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.022","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2_CR106","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","volume":"27","author":"F Huguet","year":"2009","unstructured":"Huguet F, Leguay T, Raffoux E et al (2009) Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 27(6):911\u2013918","journal-title":"J Clin Oncol"},{"issue":"12","key":"2_CR107","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","volume":"25","author":"PH Imus","year":"2019","unstructured":"Imus PH, Blackford AL, Bettinotti M et al (2019) Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 25(12):2431\u20132437. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.027","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2_CR108","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1182\/bloodadvances.2023011761","volume":"8","author":"PH Imus","year":"2024","unstructured":"Imus PH, Pasca S, Tsai HL et al (2024) Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv 8(14):3849\u20133858. https:\/\/doi.org\/10.1182\/bloodadvances.2023011761","journal-title":"Blood Adv"},{"issue":"26","key":"2_CR109","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371(26):2488\u20132498","journal-title":"N Engl J Med"},{"issue":"2","key":"2_CR110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"17","key":"2_CR111","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","volume":"6","author":"IM Johnson","year":"2022","unstructured":"Johnson IM, Bezerra ED, Farrukh F et al (2022) Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv 6(17):5227\u20135231. https:\/\/doi.org\/10.1182\/bloodadvances.2022007333","journal-title":"Blood Adv"},{"issue":"20","key":"2_CR112","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/cncr.25396","volume":"116","author":"LW Jones","year":"2010","unstructured":"Jones LW, Watson D, Herndon JE et al (2010) Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer 116(20):4825\u20134832","journal-title":"Cancer"},{"issue":"20","key":"2_CR113","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2011.39.9014","volume":"30","author":"LW Jones","year":"2012","unstructured":"Jones LW, Courneya KS, Mackey JR et al (2012) Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol 30(20):2530\u20132537","journal-title":"J Clin Oncol"},{"issue":"4","key":"2_CR114","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4235\/agmr.20.0072","volume":"24","author":"HW Jung","year":"2020","unstructured":"Jung HW, Kim S, Jang IY, Shin DW, Lee JE, Won CW (2020) Screening value of timed up and go test for frailty and low physical performance in Korean older population: the Korean Frailty and Aging Cohort Study (KFACS). Ann Geriatr Med Res 24(4):259\u2013266. https:\/\/doi.org\/10.4235\/agmr.20.0072","journal-title":"Ann Geriatr Med Res"},{"issue":"7","key":"2_CR115","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","volume":"26","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Majhail NS, Savani BN et al (2020) Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 26(7):1247\u20131256. https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2_CR116","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/qjmed\/hcaa072","volume":"113","author":"SR Kanduri","year":"2020","unstructured":"Kanduri SR, Cheungpasitporn W, Thongprayoon C et al (2020) Incidence and mortality of acute kidney injury in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. QJM 113(9):621\u2013632. https:\/\/doi.org\/10.1093\/qjmed\/hcaa072","journal-title":"QJM"},{"issue":"21","key":"2_CR117","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A et al (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677","journal-title":"J Clin Oncol"},{"issue":"15","key":"2_CR118","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","volume":"119","author":"H Kantarjian","year":"2013","unstructured":"Kantarjian H, Thomas D, Jorgensen J et al (2013) Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15):2728\u20132736","journal-title":"Cancer"},{"issue":"8","key":"2_CR119","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"issue":"9","key":"2_CR120","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"2_CR121","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L","volume":"1","author":"DA Karnofsky","year":"1948","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma: with particular reference to bronchogenic carcinoma. Cancer 1:634","journal-title":"Cancer"},{"issue":"28","key":"2_CR122","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/jco.2014.60.4777","volume":"33","author":"YL Kasamon","year":"2015","unstructured":"Kasamon YL, Bola\u00f1os-Meade J, Prince GT et al (2015) Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 33(28):3152\u20133161. https:\/\/doi.org\/10.1200\/jco.2014.60.4777","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"2_CR123","doi-asserted-by":"publisher","first-page":"12882","DOI":"10.1182\/blood-2022-168445","volume":"140","author":"R Kashyap","year":"2022","unstructured":"Kashyap R, Khalid F, Srivastav S, Malik S, Lee PC-H, Khan Z (2022) Abatacept as salvage therapy for graft-versus-host disease in allogenic hematopoietic stem cell transplantation : a systematic review. Blood 140(Supplement 1):12882\u201312883. https:\/\/doi.org\/10.1182\/blood-2022-168445","journal-title":"Blood"},{"issue":"12","key":"2_CR124","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbmt.2017.09.003","volume":"23","author":"K Kawamura","year":"2017","unstructured":"Kawamura K, Kako S, Mizuta S et al (2017) Comparison of conditioning with fludarabine\/busulfan and fludarabine\/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transplant 23(12):2079\u20132087","journal-title":"Biol Blood Marrow Transplant"},{"key":"2_CR125","doi-asserted-by":"publisher","first-page":"6186543","DOI":"10.1155\/2016\/6186543","volume":"2016","author":"CM Kelly","year":"2016","unstructured":"Kelly CM, Shahrokni A (2016) Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol 2016:6186543. https:\/\/doi.org\/10.1155\/2016\/6186543","journal-title":"J Oncol"},{"issue":"10","key":"2_CR126","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/jco.22.00958","volume":"41","author":"CL Kitko","year":"2023","unstructured":"Kitko CL, Arora M, DeFilipp Z et al (2023) Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I\/II study. J Clin Oncol 41(10):1864\u20131875. https:\/\/doi.org\/10.1200\/jco.22.00958","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR127","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/hematology.2019001299","volume":"2019","author":"HD Klepin","year":"2019","unstructured":"Klepin HD (2019) Ready for prime time: role for geriatric assessment to improve quality of care in hematology practice. Hematology Am Soc Hematol Educ Program 2019(1):53\u201358. https:\/\/doi.org\/10.1182\/hematology.2019001299","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2_CR128","doi-asserted-by":"publisher","first-page":"153473542091578","DOI":"10.1177\/1534735420915782","volume":"19","author":"S Kneis","year":"2020","unstructured":"Kneis S, Straub E, Walz ID et al (2020) Gait analysis of patients after allogeneic hematopoietic cell transplantation reveals impairments of functional performance. Integr Cancer Ther 19:1534735420915782. https:\/\/doi.org\/10.1177\/1534735420915782","journal-title":"Integr Cancer Ther"},{"issue":"4","key":"2_CR129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/leu.2017.44","volume":"31","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, Kobayashi A, Osawa Y et al (2017) Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia 31(4):1020\u20131022","journal-title":"Leukemia"},{"key":"2_CR130","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.semnephrol.2010.09.009","volume":"30","author":"A Kogon","year":"2010","unstructured":"Kogon A, Hingorani S (2010) Acute kidney injury in hematopoietic cell transplantation. Semin Nephrol (Elsevier) 30:615\u2013626","journal-title":"Semin Nephrol (Elsevier)"},{"issue":"5","key":"2_CR131","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","volume":"114","author":"HE Kohrt","year":"2009","unstructured":"Kohrt HE, Turnbull BB, Heydari K et al (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114(5):1099\u20131109. https:\/\/doi.org\/10.1182\/blood-2009-03-211441","journal-title":"Blood"},{"issue":"7","key":"2_CR132","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","volume":"98","author":"C Kollman","year":"2001","unstructured":"Kollman C, Howe CW, Anasetti C et al (2001) Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98(7):2043\u20132051","journal-title":"Blood"},{"issue":"24","key":"2_CR133","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1182\/blood.2022019107","volume":"141","author":"AG Koshy","year":"2023","unstructured":"Koshy AG, Kim HT, Liegel J et al (2023) Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 141(24):2932\u20132943. https:\/\/doi.org\/10.1182\/blood.2022019107","journal-title":"Blood."},{"issue":"19","key":"2_CR134","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1200\/jco.2016.70.7349","volume":"35","author":"N Kr\u00f6ger","year":"2017","unstructured":"Kr\u00f6ger N, Iacobelli S, Franke G-N et al (2017) Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol 35(19):2157\u20132164. https:\/\/doi.org\/10.1200\/jco.2016.70.7349","journal-title":"J Clin Oncol"},{"issue":"10","key":"2_CR135","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kr\u00f6ger","year":"2018","unstructured":"Kr\u00f6ger N, Shahnaz Syed Abd Kadir S, Zabelina T et al (2018) Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant 24(10):2152\u20132156. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2_CR136","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","volume":"36","author":"S Kunte","year":"2022","unstructured":"Kunte S, Rybicki L, Viswabandya A et al (2022) Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia 36(3):856\u2013864. https:\/\/doi.org\/10.1038\/s41375-021-01449-1","journal-title":"Leukemia"},{"issue":"4","key":"2_CR137","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11899-018-0462-x","volume":"13","author":"JT Leonard","year":"2018","unstructured":"Leonard JT, Hayes-Lattin B (2018) Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia; current evidence, and improving outcomes going forward. Curr Hematol Malig Rep 13(4):329\u2013340. https:\/\/doi.org\/10.1007\/s11899-018-0462-x","journal-title":"Curr Hematol Malig Rep"},{"issue":"Supplement 1","key":"2_CR138","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood-2018-99-110400","volume":"132","author":"A Li","year":"2018","unstructured":"Li A, Wu QV, Davis C et al (2018) The Association between transplant-associated thrombotic microangiopathy and calcineurin inhibitor and sirolimus levels. Blood 132(Supplement 1):814\u2013814. https:\/\/doi.org\/10.1182\/blood-2018-99-110400","journal-title":"Blood"},{"issue":"11","key":"2_CR139","doi-asserted-by":"crossref","first-page":"e214158","DOI":"10.1001\/jamaoncol.2021.4158","volume":"7","author":"D Li","year":"2021","unstructured":"Li D, Sun C-L, Kim H et al (2021) Geriatric assessment\u2013driven intervention (GAIN) on chemotherapy-related toxic effects in older adults with cancer: a randomized clinical trial. JAMA Oncol 7(11):e214158","journal-title":"JAMA Oncol"},{"issue":"8","key":"2_CR140","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jtct.2022.05.010","volume":"28","author":"EC Liang","year":"2022","unstructured":"Liang EC, Craig J, Torelli S et al (2022) Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia in the modern era. Transplant Cell Ther. 28(8):490\u2013495. https:\/\/doi.org\/10.1016\/j.jtct.2022.05.010","journal-title":"Transplant Cell Ther."},{"issue":"9","key":"2_CR141","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/s41409-018-0151-3","volume":"53","author":"RJ Lin","year":"2018","unstructured":"Lin RJ, Shahrokni A, Dahi PB et al (2018) Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. Bone Marrow Transplant 53(9):1184\u20131187. https:\/\/doi.org\/10.1038\/s41409-018-0151-3","journal-title":"Bone Marrow Transplant"},{"key":"2_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674093","volume":"12","author":"RJ Lin","year":"2021","unstructured":"Lin RJ, Elias HK, van den Brink MRM (2021) Immune reconstitution in the aging host: opportunities for mechanism-based therapy in allogeneic hematopoietic cell transplantation. Front Immunol 12:674093. https:\/\/doi.org\/10.3389\/fimmu.2021.674093","journal-title":"Front Immunol"},{"issue":"4","key":"2_CR143","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1182\/blood.2019000758","volume":"134","author":"MA Liu","year":"2019","unstructured":"Liu MA, DuMontier C, Murillo A et al (2019) Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood 134(4):374\u2013382. https:\/\/doi.org\/10.1182\/blood.2019000758","journal-title":"Blood"},{"issue":"11","key":"2_CR144","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/bmt.2011.46","volume":"46","author":"J Lopes","year":"2011","unstructured":"Lopes J, Jorge S (2011) Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow Transplant 46(11):1399\u20131408","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2_CR145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/bmt.2015.357","volume":"51","author":"J Lopes","year":"2016","unstructured":"Lopes J, Jorge S, Neves M (2016) Acute kidney injury in HCT: an update. Bone Marrow Transplant 51(6):755\u2013762","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2_CR146","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","volume":"153","author":"C Lopez-Otin","year":"2013","unstructured":"Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell. 153(6):1194\u20131217. https:\/\/doi.org\/10.1016\/j.cell.2013.05.039","journal-title":"Cell."},{"issue":"8","key":"2_CR147","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","volume":"99","author":"SM Lori","year":"2014","unstructured":"Lori SM, Masha K, Wendy S et al (2014) Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 99(8):1373\u20131379. https:\/\/doi.org\/10.3324\/haematol.2014.103655","journal-title":"Haematologica."},{"issue":"16","key":"2_CR148","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","volume":"115","author":"L Luznik","year":"2010","unstructured":"Luznik L, Bola\u00f1os-Meade J, Zahurak M et al (2010) High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115(16):3224\u20133230. https:\/\/doi.org\/10.1182\/blood-2009-11-251595","journal-title":"Blood"},{"issue":"3","key":"2_CR149","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE et al (2021) Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 106(3):894\u2013898. https:\/\/doi.org\/10.3324\/haematol.2020.252569","journal-title":"Haematologica."},{"issue":"3","key":"2_CR150","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","volume":"116","author":"DI Marks","year":"2010","unstructured":"Marks DI, Wang T, P\u00e9rez WS et al (2010) The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia in first and second complete remission. Blood 116(3):366\u2013374","journal-title":"Blood"},{"issue":"16","key":"2_CR151","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795\u20131802","journal-title":"J Clin Oncol"},{"issue":"3","key":"2_CR152","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11899-011-0093-y","volume":"6","author":"MS Mathisen","year":"2011","unstructured":"Mathisen MS, O'Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F (2011) Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep 6(3):187\u2013194. https:\/\/doi.org\/10.1007\/s11899-011-0093-y","journal-title":"Curr Hematol Malig Rep"},{"issue":"Supplement 1","key":"2_CR153","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2021-146997","volume":"138","author":"MJ McAdams","year":"2021","unstructured":"McAdams MJ, Hyder M, Dimitrova D et al (2021) Phase I\/II study of reduced dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood 138(Supplement 1):101\u2013101. https:\/\/doi.org\/10.1182\/blood-2021-146997","journal-title":"Blood"},{"issue":"11","key":"2_CR154","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL et al (2010) Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 28(11):1878\u20131887. https:\/\/doi.org\/10.1200\/JCO.2009.25.4821","journal-title":"J Clin Oncol."},{"issue":"10","key":"2_CR155","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.bbmt.2018.06.004","volume":"24","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Muth ST, Tsai HL et al (2018) Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transplant 24(10):2056\u20132064. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2_CR156","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtct.2023.12.021","volume":"30","author":"SR McCurdy","year":"2024","unstructured":"McCurdy SR, Hyder MA, Sabina R et al (2024) Interim results of a phase I\/II trial of intermediate-dose post-transplantation cyclophosphamide after reduced intensity conditioned hla-mismatched bone marrow transplantation for older or unfit patients. Transplant Cell Ther 30(2):S2\u2013S3. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2_CR157","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","volume":"25","author":"D McLornan","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L et al (2019) Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 25(11):2167\u20132171. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.034","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2_CR158","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","volume":"97","author":"PA McSweeney","year":"2001","unstructured":"McSweeney PA, Niederwieser D, Shizuru JA et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97(11):3390\u20133400","journal-title":"Blood"},{"issue":"10","key":"2_CR159","doi-asserted-by":"publisher","first-page":"695.e1","DOI":"10.1016\/j.jtct.2022.07.021","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Rondon G et al (2022) Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation. Transplant Cell Therapy 28(10):695.e1\u2013695.e10. https:\/\/doi.org\/10.1016\/j.jtct.2022.07.021","journal-title":"Transplant Cell Therapy"},{"issue":"8","key":"2_CR160","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1182\/bloodadvances.2022009240","volume":"7","author":"RS Mehta","year":"2023","unstructured":"Mehta RS, Marin D, Alousi A et al (2023) Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv. 7(8):1594\u20131603. https:\/\/doi.org\/10.1182\/bloodadvances.2022009240","journal-title":"Blood Adv."},{"key":"2_CR161","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/bloodadvances.2024013853","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Ramdial J, Kebriaei P et al (2024) Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv 8:5306. https:\/\/doi.org\/10.1182\/bloodadvances.2024013853","journal-title":"Blood Adv"},{"issue":"6","key":"2_CR162","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.nefroe.2022.11.006","volume":"42","author":"MM Menezes","year":"2022","unstructured":"Menezes MM, Marques AI, Chuva T et al (2022) Acute kidney injury after allogeneic hematopoietic stem cell transplantation \u2013 predictors and survival impact: a single center retrospective study. Nefrolog\u00eda (English Edition) 42(6):656\u2013663. https:\/\/doi.org\/10.1016\/j.nefroe.2022.11.006","journal-title":"Nefrolog\u00eda (English Edition)"},{"issue":"12","key":"2_CR163","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.6004\/jnccn.2019.7327","volume":"17","author":"C Meyer","year":"2019","unstructured":"Meyer C, Mau L-W, Murphy EA et al (2019) Addressing knowledge gaps in acute myeloid leukemia to improve referral for hematopoietic cell transplantation consultation. J Natl Compr Cancer Netw 17(12):1473\u20131481","journal-title":"J Natl Compr Cancer Netw"},{"issue":"7","key":"2_CR164","doi-asserted-by":"publisher","first-page":"617.e1","DOI":"10.1016\/j.jtct.2021.03.028","volume":"27","author":"A Mishra","year":"2021","unstructured":"Mishra A, Preussler JM, Bhatt VR et al (2021) Breaking the age barrier: physicians\u2019 perceptions of candidacy for allogeneic hematopoietic cell transplantation in older adults. Transplant Cell Therapy 27(7):617.e1\u2013617.e7. https:\/\/doi.org\/10.1016\/j.jtct.2021.03.028","journal-title":"Transplant Cell Therapy"},{"key":"2_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779881","volume":"12","author":"M Miyata","year":"2021","unstructured":"Miyata M, Ichikawa K, Matsuki E, Watanabe M, Peltier D, Toubai T (2021) Recent advances of acute kidney injury in hematopoietic cell transplantation. Front Immunol 12:779881. https:\/\/doi.org\/10.3389\/fimmu.2021.779881","journal-title":"Front Immunol"},{"issue":"2","key":"2_CR166","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","volume":"6","author":"SG Mohile","year":"2020","unstructured":"Mohile SG, Epstein RM, Hurria A et al (2020) Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program. JAMA Oncol 6(2):196\u2013204","journal-title":"JAMA Oncol"},{"issue":"10314","key":"2_CR167","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","volume":"398","author":"SG Mohile","year":"2021","unstructured":"Mohile SG, Mohamed MR, Xu H et al (2021) Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. Lancet 398(10314):1894\u20131904","journal-title":"Lancet"},{"issue":"22","key":"2_CR168","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L et al (2010) Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 116(22):4439\u20134443","journal-title":"Blood"},{"issue":"9","key":"2_CR169","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M et al (2017) Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130(9):1156\u20131164. https:\/\/doi.org\/10.1182\/blood-2017-03-772368","journal-title":"Blood"},{"issue":"3","key":"2_CR170","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","volume":"10","author":"A Murillo","year":"2019","unstructured":"Murillo A, Cronin AM, Laubach JP et al (2019) Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. J Geriatr Oncol 10(3):486\u2013489. https:\/\/doi.org\/10.1016\/j.jgo.2018.10.010","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2_CR171","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/10428194.2023.2300708","volume":"65","author":"MU Mushtaq","year":"2024","unstructured":"Mushtaq MU, Shahzad M, Amin MK et al (2024) Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leuk Lymphoma 65(4):493\u2013502. https:\/\/doi.org\/10.1080\/10428194.2023.2300708","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2_CR172","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1182\/blood.2020005397","volume":"136","author":"M Myllym\u00e4ki","year":"2020","unstructured":"Myllym\u00e4ki M, Redd R, Reilly CR et al (2020) Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood 136(26):3070\u20133081. https:\/\/doi.org\/10.1182\/blood.2020005397","journal-title":"Blood"},{"key":"2_CR173","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood.V86.3.1228.1228","volume":"86","author":"A Nademanee","year":"1995","unstructured":"Nademanee A, Schmidt GM, Parker P et al (1995) The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone. Blood 86:1228","journal-title":"Blood"},{"issue":"30","key":"2_CR174","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1200\/jco.20.03380","volume":"39","author":"R Nakamura","year":"2021","unstructured":"Nakamura R, Saber W, Martens MJ et al (2021) Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome. J Clin Oncol 39(30):3328\u20133339. https:\/\/doi.org\/10.1200\/jco.20.03380","journal-title":"J Clin Oncol"},{"key":"2_CR175","unstructured":"National Cancer Institute (2024) Bethesda M. SEER Cancer Stat Facts: Acute Myeloid Leukemia. Accessed May 21, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"issue":"8","key":"2_CR176","doi-asserted-by":"crossref","first-page":"662.e1","DOI":"10.1016\/j.jtct.2021.04.014","volume":"27","author":"LF Newell","year":"2021","unstructured":"Newell LF, Williams T, Liu J et al (2021a) Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse. Transplant Cell Therapy 27(8):662.e1\u2013662.e9","journal-title":"Transplant Cell Therapy"},{"issue":"8","key":"2_CR177","doi-asserted-by":"publisher","first-page":"662.e1","DOI":"10.1016\/j.jtct.2021.04.014","volume":"27","author":"LF Newell","year":"2021","unstructured":"Newell LF, Williams T, Liu J et al (2021b) Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic graft-versus-host disease requiring immunosuppressive therapy, but no adverse impact on overall survival or relapse. Transplant Cell Ther. 27(8):662.e1\u2013662.e9. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.014","journal-title":"Transplant Cell Ther."},{"issue":"8","key":"2_CR178","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41409-024-02282-7","volume":"59","author":"C Niederwieser","year":"2024","unstructured":"Niederwieser C, Iacobelli S, Franke G-N et al (2024) Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant 59(8):1084\u20131091. https:\/\/doi.org\/10.1038\/s41409-024-02282-7","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2_CR179","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013656","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"2_CR180","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/bloodadvances.2020001719","volume":"4","author":"RL Olin","year":"2020","unstructured":"Olin RL, Fretham C, Pasquini MC et al (2020) Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. Blood Adv. 4(12):2810\u20132820. https:\/\/doi.org\/10.1182\/bloodadvances.2020001719","journal-title":"Blood Adv."},{"issue":"11","key":"2_CR181","doi-asserted-by":"publisher","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","volume":"27","author":"B Oran","year":"2021","unstructured":"Oran B, Ahn KW, Fretham C et al (2021) Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes. Transplant Cell Therapy 27(11):921.e1\u2013921.e10. https:\/\/doi.org\/10.1016\/j.jtct.2021.08.007","journal-title":"Transplant Cell Therapy"},{"issue":"3","key":"2_CR182","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.ki.5000055","volume":"69","author":"C Parikh","year":"2006","unstructured":"Parikh C, Coca S (2006) Acute renal failure in hematopoietic cell transplantation. Kidney Int 69(3):430\u2013435","journal-title":"Kidney Int"},{"issue":"3","key":"2_CR183","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1053\/j.ajkd.2004.11.013","volume":"45","author":"CR Parikh","year":"2005","unstructured":"Parikh CR, Schrier RW, Storer B et al (2005) Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 45(3):502\u2013509","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2_CR184","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.12828","volume":"93","author":"F Patriarca","year":"2008","unstructured":"Patriarca F, Bacigalupo A, Sperotto A et al (2008) Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93(10):1514\u20131522. https:\/\/doi.org\/10.3324\/haematol.12828","journal-title":"Haematologica"},{"issue":"5","key":"2_CR185","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41409-024-02207-4","volume":"59","author":"T Pattipaka","year":"2024","unstructured":"Pattipaka T, Sarp S, Nakhaei P, G\u00fcne\u015f S (2024) Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program. Bone Marrow Transplant 59(5):637\u2013646. https:\/\/doi.org\/10.1038\/s41409-024-02207-4","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2_CR186","doi-asserted-by":"publisher","first-page":"697.e1","DOI":"10.1016\/j.jtct.2023.08.009","volume":"29","author":"MP Pereira","year":"2023","unstructured":"Pereira MP, Remberger M, Chen C et al (2023) Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 29(11):697.e1\u2013697.e10. https:\/\/doi.org\/10.1016\/j.jtct.2023.08.009","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"2_CR187","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","volume":"39","author":"D Podsiadlo","year":"1991","unstructured":"Podsiadlo D, Richardson S (1991) The timed \u201cup & go\u201d: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142\u2013148. https:\/\/doi.org\/10.1111\/j.1532-5415.1991.tb01616.x","journal-title":"J Am Geriatr Soc"},{"key":"2_CR188","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2018-99-117179","volume":"132","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Pratz KW, Jonas BA et al (2018) Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Blood 132:285","journal-title":"Blood"},{"issue":"20","key":"2_CR189","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1182\/bloodadvances.2023010850","volume":"7","author":"UR Popat","year":"2023","unstructured":"Popat UR, Pasvolsky O, Bassett R Jr et al (2023) Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196\u20136205. https:\/\/doi.org\/10.1182\/bloodadvances.2023010850","journal-title":"Blood Adv"},{"issue":"Suppl","key":"2_CR190","doi-asserted-by":"crossref","first-page":"LID \u2013 e68978fe","DOI":"10.1097\/01.HS9.0000969008.68978.fe","volume":"7","author":"K Pratz","year":"2023","unstructured":"Pratz K, Dinardo C, Arellano ML et al (2023) P525: long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HMA therapies. Hemasphere. 7(Suppl):LID \u2013 e68978fe. (2572-9241 (Electronic))","journal-title":"Hemasphere."},{"issue":"11","key":"2_CR191","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41409-023-02043-y","volume":"58","author":"S Raghunandan","year":"2023","unstructured":"Raghunandan S, Qayed M, Watkins BK et al (2023) Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies. Bone Marrow Transplant 58(11):1264\u20131266. https:\/\/doi.org\/10.1038\/s41409-023-02043-y","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2_CR192","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.bbmt.2018.04.010","volume":"24","author":"RV Raj","year":"2018","unstructured":"Raj RV, Hamadani M, Szabo A et al (2018) Peripheral blood grafts for T cell\u2013replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant 24(8):1664\u20131670. https:\/\/doi.org\/10.1016\/j.bbmt.2018.04.010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2_CR193","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1053\/bbmt.2002.v8.abbmt080674","volume":"8","author":"M Remberger","year":"2002","unstructured":"Remberger M, Kumlien G, Aschan J et al (2002) Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8(12):674\u2013682. https:\/\/doi.org\/10.1053\/bbmt.2002.v8.abbmt080674","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2_CR194","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbmt.2009.07.005","volume":"15","author":"E Richa","year":"2009","unstructured":"Richa E, Papari M, Allen J et al (2009) Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 15(11):1394\u20131399","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2_CR195","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C et al (2005) A global clinical measure of fitness and frailty in elderly people. CMAJ 173(5):489\u2013495. https:\/\/doi.org\/10.1503\/cmaj.050051","journal-title":"CMAJ"},{"issue":"6","key":"2_CR196","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/oxfordjournals.annonc.a057981","volume":"2","author":"F Roila","year":"1991","unstructured":"Roila F, Lupattelli M, Sassi M et al (1991) Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 2(6):437\u2013439","journal-title":"Ann Oncol"},{"issue":"68","key":"2_CR197","doi-asserted-by":"publisher","first-page":"112972","DOI":"10.18632\/oncotarget.22934","volume":"8","author":"G Roth-Guepin","year":"2017","unstructured":"Roth-Guepin G, Canaani J, Ruggeri A et al (2017) Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT. Oncotarget 8(68):112972\u2013112979. https:\/\/doi.org\/10.18632\/oncotarget.22934","journal-title":"Oncotarget"},{"issue":"3","key":"2_CR198","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.bbmt.2019.12.095","volume":"26","author":"RM Saliba","year":"2020","unstructured":"Saliba RM, Arora M, Spellman SR et al (2020) Acute graft-versus-host disease is less severe and associated with lower non-relapse mortality after haploidentical transplantation with post-cyclophosphamide prophylaxis. Biol Blood Marrow Transplant 26(3):S26\u2013S27","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2_CR199","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-018-0598-0","volume":"11","author":"N Santoro","year":"2018","unstructured":"Santoro N, Labopin M, Giannotti F et al (2018) Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 11(1):55. https:\/\/doi.org\/10.1186\/s13045-018-0598-0","journal-title":"J Hematol Oncol."},{"issue":"4","key":"2_CR200","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2991\/chi.k.210731.001","volume":"3","author":"F Saraceni","year":"2021","unstructured":"Saraceni F, Scortechini I, Fiorentini A et al (2021) Conditioning regimens for frail patients with acute leukemia undergoing allogeneic stem cell transplant: how to strike gently. Clin Hematol Int 3(4):153\u2013160. https:\/\/doi.org\/10.2991\/chi.k.210731.001","journal-title":"Clin Hematol Int"},{"issue":"4","key":"2_CR201","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/gerona\/gls190","volume":"68","author":"GM Savva","year":"2012","unstructured":"Savva GM, Donoghue OA, Horgan F, O\u2019Regan C, Cronin H, Kenny RA (2012) Using timed up-and-go to identify frail members of the older population. J Gerontol Ser A 68(4):441\u2013446. https:\/\/doi.org\/10.1093\/gerona\/gls190","journal-title":"J Gerontol Ser A"},{"issue":"Supplement 1","key":"2_CR202","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/blood-2023-180531","volume":"142","author":"J Schetelig","year":"2023","unstructured":"Schetelig J, Baldauf H, Rave C et al (2023) Unrelated donors below 35 years of age should be preferred over HLA-matched sibling donors older than 50 years for patients with myeloid malignancies. Blood 142(Supplement 1):1046\u20131046. https:\/\/doi.org\/10.1182\/blood-2023-180531","journal-title":"Blood"},{"issue":"30","key":"2_CR203","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2010.28.6856","volume":"28","author":"RF Schlenk","year":"2010","unstructured":"Schlenk RF, D\u00f6hner K, Mack S et al (2010) Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 28(30):4642\u20134648","journal-title":"J Clin Oncol"},{"issue":"8","key":"2_CR204","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR et al (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118(8):2077\u20132084. https:\/\/doi.org\/10.1182\/blood-2011-03-338707","journal-title":"Blood"},{"issue":"11","key":"2_CR205","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR et al (2017) Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 35(11):1154\u20131161. https:\/\/doi.org\/10.1200\/JCO.2016.70.7091","journal-title":"J Clin Oncol."},{"issue":"6","key":"2_CR206","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M et al (2021) Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial. Transplant Cell Ther. 27(6):483.e1\u2013483.e6. https:\/\/doi.org\/10.1016\/j.jtct.2021.02.031","journal-title":"Transplant Cell Ther."},{"issue":"9","key":"2_CR207","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jama.2022.14578","volume":"328","author":"MA Sekeres","year":"2022","unstructured":"Sekeres MA, Taylor J (2022) Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA 328(9):872\u2013880. https:\/\/doi.org\/10.1001\/jama.2022.14578","journal-title":"JAMA"},{"issue":"18","key":"2_CR208","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1200\/JCO.20.03502","volume":"39","author":"BE Shaw","year":"2021","unstructured":"Shaw BE, Jimenez-Jimenez AM, Burns LJ et al (2021) National marrow donor program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide. J Clin Oncol. 39(18):1971\u20131982. https:\/\/doi.org\/10.1200\/JCO.20.03502","journal-title":"J Clin Oncol."},{"issue":"2","key":"2_CR209","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/sj.leu.2404037","volume":"20","author":"A Shimoni","year":"2006","unstructured":"Shimoni A, Hardan I, Shem-Tov N et al (2006) Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 20(2):322\u2013328. https:\/\/doi.org\/10.1038\/sj.leu.2404037","journal-title":"Leukemia"},{"issue":"12","key":"2_CR210","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/bmt.2015.188","volume":"50","author":"N Shingai","year":"2015","unstructured":"Shingai N, Morito T, Najima Y et al (2015) Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. Bone Marrow Transplant 50(12):1557\u20131562","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2_CR211","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","volume":"128","author":"NJ Short","year":"2016","unstructured":"Short NJ, Jabbour E, Sasaki K et al (2016) Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504\u2013507. https:\/\/doi.org\/10.1182\/blood-2016-03-707562","journal-title":"Blood"},{"issue":"9","key":"2_CR213","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/S2666-7568(22)00169-6","volume":"3","author":"WK Soo","year":"2022","unstructured":"Soo WK, King MT, Pope A, Parente P, D\u0101rzi\u0146\u0161 P, Davis ID (2022) Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a multicentre, open-label, randomised controlled trial. Lancet Healthy Longevity 3(9):e617\u2013e627","journal-title":"Lancet Healthy Longevity"},{"issue":"4","key":"2_CR214","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","volume":"67","author":"J S\u00f8rensen","year":"1993","unstructured":"S\u00f8rensen J, Klee M, Palshof T, Hansen H (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773\u2013775","journal-title":"Br J Cancer"},{"issue":"8","key":"2_CR215","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919. https:\/\/doi.org\/10.1182\/blood-2005-05-2004","journal-title":"Blood"},{"issue":"6","key":"2_CR216","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2009.02.007","volume":"15","author":"ML Sorror","year":"2009","unstructured":"Sorror ML, Storer B, Storb RF (2009) Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 15(6):757\u2013758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2_CR217","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2014-01-550566","volume":"124","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Martin PJ, Storb RF et al (2014) Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 124(2):287\u2013295. https:\/\/doi.org\/10.1182\/blood-2014-01-550566","journal-title":"Blood"},{"issue":"1","key":"2_CR218","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","volume":"17","author":"AS Sperling","year":"2017","unstructured":"Sperling AS, Gibson CJ, Ebert BL (2017) The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer 17(1):5\u201319. https:\/\/doi.org\/10.1038\/nrc.2016.112","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"2_CR219","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/ajh.25647","volume":"94","author":"SA Srour","year":"2019","unstructured":"Srour SA, Saliba RM, Bittencourt MCB et al (2019) Haploidentical transplantation for acute myeloid leukemia patients with minimal\/measurable residual disease at transplantation. Am J Hematol 94(12):1382\u20131387. https:\/\/doi.org\/10.1002\/ajh.25647","journal-title":"Am J Hematol"},{"issue":"10","key":"2_CR220","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/ajh.25924","volume":"95","author":"SA Srour","year":"2020","unstructured":"Srour SA, Kongtim P, Rondon G et al (2020) Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol 95(10):1187\u20131192. https:\/\/doi.org\/10.1002\/ajh.25924","journal-title":"Am J Hematol"},{"issue":"3","key":"2_CR221","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/jco.23.00546","volume":"42","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Raffel S, Alakel N et al (2024) Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia Chromosome-Negative B-Precursor ALL. J Clin Oncol 42(3):273\u2013282. https:\/\/doi.org\/10.1200\/jco.23.00546","journal-title":"J Clin Oncol"},{"issue":"21","key":"2_CR222","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","volume":"124","author":"W Stock","year":"2014","unstructured":"Stock W, Luger SM, Advani AS et al (2014) Favorable outcomes for older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): early results of U.S. Intergroup Trial C10403. Blood 124(21):796\u2013796. https:\/\/doi.org\/10.1182\/blood.V124.21.796.796","journal-title":"Blood"},{"issue":"8","key":"2_CR223","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41375-018-0042-z","volume":"32","author":"J Su\u00e1rez-Gonz\u00e1lez","year":"2018","unstructured":"Su\u00e1rez-Gonz\u00e1lez J, Martinez-Laperche C, Mart\u00ednez N et al (2018) Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis. Leukemia 32(8):1822\u20131826","journal-title":"Leukemia"},{"issue":"4","key":"2_CR224","doi-asserted-by":"publisher","first-page":"415.e1","DOI":"10.1016\/j.jtct.2024.01.062","volume":"30","author":"AD Sung","year":"2024","unstructured":"Sung AD, Koll T, Gier SH et al (2024) Preconditioning frailty phenotype influences survival and relapse for older allogeneic transplantation recipients. Transplant Cell Ther 30(4):415.e1\u2013415.e16. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.062","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2_CR225","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/bmt.2013.68","volume":"48","author":"J Tanaka","year":"2013","unstructured":"Tanaka J, Kanamori H, Nishiwaki S et al (2013) Reduced-intensity vs myeloablative conditioning allogeneic hematopoietic SCT for patients aged over 45 years with ALL in remission: a study from the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Bone Marrow Transplant 48(11):1389\u20131394","journal-title":"Bone Marrow Transplant"},{"issue":"36","key":"2_CR226","doi-asserted-by":"publisher","first-page":"9387","DOI":"10.1200\/jco.2005.02.0057","volume":"23","author":"S Tauro","year":"2005","unstructured":"Tauro S, Craddock C, Peggs K et al (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23(36):9387\u20139393. https:\/\/doi.org\/10.1200\/jco.2005.02.0057","journal-title":"J Clin Oncol"},{"issue":"17","key":"2_CR227","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL et al (2018) MIPSS70+ Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 36(17):1769\u20131770. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867","journal-title":"J Clin Oncol."},{"issue":"2","key":"2_CR228","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/jco.1990.8.2.272","volume":"8","author":"H Tilly","year":"1990","unstructured":"Tilly H, Castaigne S, Bordessoule D et al (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8(2):272\u2013279. https:\/\/doi.org\/10.1200\/jco.1990.8.2.272","journal-title":"J Clin Oncol"},{"issue":"2, Supplement","key":"2_CR229","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/j.jtct.2023.12.367","volume":"30","author":"P Tonzi","year":"2024","unstructured":"Tonzi P, Hsu J, Cole K et al (2024) Clinical burden of GvHD in patients receiving CAST for prophylaxis following peripheral blood haploidentical hematopoietic stem cell transplant. Transplant Cell Ther 30(2, Supplement):S274. https:\/\/doi.org\/10.1016\/j.jtct.2023.12.367","journal-title":"Transplant Cell Ther"},{"issue":"36","key":"2_CR230","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134\u20134140","journal-title":"J Clin Oncol"},{"issue":"1","key":"2_CR231","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366","journal-title":"Lancet Oncol"},{"issue":"8","key":"2_CR232","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/cam4.3731","volume":"10","author":"MS Topp","year":"2021","unstructured":"Topp MS, Stein AS, G\u00f6kbuget N et al (2021) Blinatumomab as first salvage versus second or later salvage in adults with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia: results of a pooled analysis. Cancer Med 10(8):2601\u20132610","journal-title":"Cancer Med"},{"issue":"11","key":"2_CR233","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","volume":"33","author":"C Ustun","year":"2019","unstructured":"Ustun C, Le-Rademacher J, Wang HL et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia 33(11):2599\u20132609. https:\/\/doi.org\/10.1038\/s41375-019-0477-x","journal-title":"Leukemia"},{"issue":"7","key":"2_CR234","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1038\/s41409-020-0839-z","volume":"55","author":"O Uziel","year":"2020","unstructured":"Uziel O, Lahav M, Shargian L et al (2020) Premature ageing following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 55(7):1438\u20131446. https:\/\/doi.org\/10.1038\/s41409-020-0839-z","journal-title":"Bone Marrow Transplant"},{"key":"2_CR235","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.630186","volume":"11","author":"A Vaiserman","year":"2020","unstructured":"Vaiserman A, Krasnienkov D (2020) Telomere length as a marker of biological age: state-of-the-art, open issues, and future perspectives. Front Genet 11:630186. https:\/\/doi.org\/10.3389\/fgene.2020.630186","journal-title":"Front Genet"},{"issue":"4","key":"2_CR236","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/jco.2007.11.1641","volume":"26","author":"D Valc\u00e1rcel","year":"2008","unstructured":"Valc\u00e1rcel D, Martino R, Caballero D et al (2008) Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 26(4):577\u2013584. https:\/\/doi.org\/10.1200\/jco.2007.11.1641","journal-title":"J Clin Oncol."},{"issue":"24","key":"2_CR237","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1200\/jco.2005.15.602","volume":"23","author":"K van Besien","year":"2005","unstructured":"van Besien K, Artz A, Smith S et al (2005) Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5728\u20135738. https:\/\/doi.org\/10.1200\/jco.2005.15.602","journal-title":"J Clin Oncol"},{"issue":"6","key":"2_CR238","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaccao.2023.07.007","volume":"5","author":"A Vasbinder","year":"2023","unstructured":"Vasbinder A, Hoeger CW, Catalan T et al (2023) Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors. JACC Cardio Oncol 5(6):821\u2013832. https:\/\/doi.org\/10.1016\/j.jaccao.2023.07.007","journal-title":"JACC Cardio Oncol"},{"issue":"13","key":"2_CR239","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/bloodadvances.2017015222","volume":"2","author":"S Vasu","year":"2018","unstructured":"Vasu S, Kohlschmidt J, Mr\u00f3zek K et al (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2(13):1645\u20131650. https:\/\/doi.org\/10.1182\/bloodadvances.2017015222","journal-title":"Blood Adv"},{"issue":"8\u20139","key":"2_CR240","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/0959-8049(92)90510-9","volume":"28","author":"E Verger","year":"1992","unstructured":"Verger E, Salamero M, Conill C (1992) Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 28(8\u20139):1328\u20131330","journal-title":"Eur J Cancer"},{"issue":"6","key":"2_CR241","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/jci124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG (2019) Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 129(6):2357\u20132373. https:\/\/doi.org\/10.1172\/jci124218","journal-title":"J Clin Invest."},{"issue":"2","key":"2_CR242","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","volume":"26","author":"LP Wachsmuth","year":"2020","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Kanakry CG (2020) Optimized timing of post-transplantation cyclophosphamide in mhc-haploidentical murine hematopoietic cell transplantation. Biol Blood Marrow Transplant 26(2):230\u2013241. https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.030","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2_CR243","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/leu.2010.102","volume":"24","author":"RB Walter","year":"2010","unstructured":"Walter RB, Pagel JM, Gooley TA et al (2010) Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia 24(7):1276\u20131282","journal-title":"Leukemia"},{"key":"2_CR244","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arr.2018.09.002","volume":"48","author":"Q Wang","year":"2018","unstructured":"Wang Q, Zhan Y, Pedersen NL, Fang F, H\u00e4gg S (2018) Telomere length and all-cause mortality: a meta-analysis. Ageing Res Rev 48:11\u201320","journal-title":"Ageing Res Rev"},{"issue":"17","key":"2_CR245","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/jco.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C et al (2021) Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD. J Clin Oncol 39(17):1865\u20131877. https:\/\/doi.org\/10.1200\/jco.20.01086","journal-title":"J Clin Oncol"},{"issue":"3","key":"2_CR246","doi-asserted-by":"publisher","first-page":"182.e1","DOI":"10.1016\/j.jtct.2022.12.018","volume":"29","author":"JA Webster","year":"2023","unstructured":"Webster JA, Reed M, Tsai HL et al (2023) Allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide for acute lymphoblastic leukemia in patients age \u226555 years. Transplant Cell Ther. 29(3):182.e1\u2013182.e8. https:\/\/doi.org\/10.1016\/j.jtct.2022.12.018","journal-title":"Transplant Cell Ther."},{"issue":"6","key":"2_CR247","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/00007890-199106000-00010","volume":"51","author":"D Weisdorf","year":"1991","unstructured":"Weisdorf D, Hakke R, Blazar B et al (1991) Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 51(6):1197\u20131202","journal-title":"Transplantation"},{"issue":"6","key":"2_CR248","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13752","volume":"31","author":"J Welford","year":"2022","unstructured":"Welford J, Rafferty R, Hunt K et al (2022) The Clinical Frailty Scale can indicate prognosis and care requirements on discharge in oncology and haemato-oncology inpatients: a cohort study. Eur J Cancer Care 31(6):e13752. https:\/\/doi.org\/10.1111\/ecc.13752","journal-title":"Eur J Cancer Care"},{"issue":"3","key":"2_CR249","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00277-021-04434-x","volume":"100","author":"T Wertheimer","year":"2021","unstructured":"Wertheimer T, Dohse M, Afram G et al (2021) Abatacept as salvage therapy in chronic graft-versus-host disease\u2014a retrospective analysis. Ann Hematol 100(3):779\u2013787. https:\/\/doi.org\/10.1007\/s00277-021-04434-x","journal-title":"Ann Hematol"},{"issue":"9","key":"2_CR250","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/op.23.00263","volume":"19","author":"GR Williams","year":"2023","unstructured":"Williams GR, Hopkins JO, Klepin HD et al (2023) Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline questions and answers. JCO Oncol Pract 19(9):718\u2013723. https:\/\/doi.org\/10.1200\/op.23.00263","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"2_CR251","doi-asserted-by":"publisher","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","volume":"28","author":"AC Winters","year":"2022","unstructured":"Winters AC, Bosma G, Abbott D et al (2022) Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transplant Cell Ther 28(10):694.e1\u2013694.e9. https:\/\/doi.org\/10.1016\/j.jtct.2022.07.022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2_CR252","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/bmt.2013.58","volume":"48","author":"W Wood","year":"2013","unstructured":"Wood W, Deal A, Reeve B et al (2013) Cardiopulmonary fitness in patients undergoing hematopoietic SCT: a pilot study. Bone Marrow Transplant 48(10):1342\u20131349","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2_CR253","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1182\/blood-2010-12-326322","volume":"117","author":"H Xiao","year":"2011","unstructured":"Xiao H, Shi J, Luo Y et al (2011) First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood 117(19):5257\u20135260","journal-title":"Blood"},{"issue":"12","key":"2_CR254","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, Lu C, Wang J et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20(12):1472\u20131478. https:\/\/doi.org\/10.1038\/nm.3733","journal-title":"Nat Med"},{"issue":"1","key":"2_CR255","first-page":"5046867","volume":"2019","author":"X Xu","year":"2019","unstructured":"Xu X, Hu H, Lin Y et al (2019) Differences in leukocyte telomere length between coronary heart disease and normal population: a multipopulation meta-analysis. Biomed Res Int 2019(1):5046867","journal-title":"Biomed Res Int"},{"issue":"12","key":"2_CR256","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/cncr.21932","volume":"106","author":"M Yanada","year":"2006","unstructured":"Yanada M, Matsuo K, Suzuki T, Naoe T (2006) Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia. Cancer 106(12):2657\u20132663. https:\/\/doi.org\/10.1002\/cncr.21932","journal-title":"Cancer"},{"issue":"19","key":"2_CR257","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, Bubnoff NV, Butler J et al (2020a) Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 382(19):1800\u20131810. https:\/\/doi.org\/10.1056\/NEJMoa1917635","journal-title":"N Engl J Med"},{"key":"2_CR258","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-137694","volume":"136","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, Polverelli N, Ram R et al (2020b) Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory\/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. Blood 136:22\u201324","journal-title":"Blood"},{"issue":"3","key":"2_CR259","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R et al (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385(3):228\u2013238","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"2_CR260","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1182\/blood-2023-189430","volume":"142","author":"H Zhang","year":"2023","unstructured":"Zhang H, Dong T, Liu Z et al (2023) Phase I\/II study of reduced dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-identical peripheral blood hematopoietic stem cell transplantation. Blood 142(Supplement 1):650\u2013650. https:\/\/doi.org\/10.1182\/blood-2023-189430","journal-title":"Blood"},{"issue":"7","key":"2_CR261","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41409-024-02266-7","volume":"59","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao X, Chen S et al (2024) Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients. Bone Marrow Transplant 59(7):997\u20131005. https:\/\/doi.org\/10.1038\/s41409-024-02266-7","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2_CR262","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1007\/s00277-023-05500-2","volume":"102","author":"X Zheng","year":"2023","unstructured":"Zheng X, Gao H, Lu N et al (2023) Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Ann Hematol 102(12):3603\u20133611. https:\/\/doi.org\/10.1007\/s00277-023-05500-2","journal-title":"Ann Hematol"}],"container-title":["Advances in Experimental Medicine and Biology","Clinical Management of Challenges in Allogeneic Stem Cell Transplant"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-84988-6_2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T06:56:23Z","timestamp":1749452183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-84988-6_2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031849879","9783031849886"],"references-count":260,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-84988-6_2","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"10 June 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}